YD Bio Ltd Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
No analyst estimates are published for this company.
Coverage varies across the market: larger companies are often followed by dozens of analysts, while smaller or recently listed ones may have none.
Monitoring Framework
Key Performance Indicators
Net Revenue Annually596.8K
Net Loss Annually-8.3M
Cash and Cash Equivalents Annually6M
Watch Items
- EG BioMed Merger Definitive AgreementTrigger: Execution of definitive merger agreementAction: Monitor SEC filings (Form 6-K) for transition from non-binding MOU to definitive agreement.
- Going Concern Status and Cash BurnTrigger: Cash reserves falling below 12 months of operating runwayAction: Evaluate capital raising activities, warrant exercises, or further PIPE financing to address going concern warnings.
- IND Submissions for Dry Eye Disease and AMDTrigger: Filing of IND applications with the FDA in 2026Action: Track clinical roadmap milestones and FDA feedback on Limbal Stem Cell and exosome platforms.
Research as of 19 Jun 2026